Results 31 to 40 of about 3,601 (174)

Preparation of a camptothecin analog FLQY2 self-micelle solid dispersion with improved solubility and bioavailability

open access: yesJournal of Nanobiotechnology, 2022
Background 7-p-trifluoromethylphenyl-FL118 (FLQY2) is a camptothecin analog with excellent antitumor efficacy against various solid tumors. However, its poor solubility and low bioavailability limited the development of the drug.
Yi Wang   +6 more
doaj   +1 more source

Development and Targeting Efficiency of Irinotecan Engineered Proniosomes [PDF]

open access: yes, 2012
Purpose: This study is aimed at achieving improvement in the efficacy, reduced toxicity and enhancement of therapeutic index of irinotecan. Methods: Proniosomes of irinotecan hydrochloride trihydrate were prepared by slurry method using different ...
Joshi, Vijay G, Goudanavar, Prakash S
core   +5 more sources

Self-Monitoring and Self-Delivery of Self-Assembled Fluorescent Nanoparticles in Cancer Therapy

open access: yesInternational Journal of Nanomedicine, 2021
Hongmei Liu,1,2 Minghao Yuan,1,2 Yushi Liu,1,2 Yiping Guo,3 Haijun Xiao,4 Li Guo,1,2 Fei Liu1,2 1School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, People’s Republic of China; 2State Key Laboratory of ...
Liu H   +6 more
doaj  

Problems on the approval of irinotecan hydrochloride. [PDF]

open access: yesRinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 1997
ROKURO HAMA
openaire   +3 more sources

RP-HPLC method development and validation for the simultaneous estimation of Irinotecan hydrochloride and Capecitabine in Active Pharmaceutical Ingredients (APIs) [PDF]

open access: yes, 2018
The combination of Irinotecan Hydrochloride (IRI) and Capecitabine (CAP) is indicated for the treatment of cancer. IRI and CAP were developed by an simultaneous simple reverse phase liquid chromatographic method and were subsequently validated from their
Varalakshmi Devi K   +3 more
core   +1 more source

Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. [PDF]

open access: yes, 2017
The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Shire Pharmaceuticals) of pegylated liposomal irinotecan hydrochloride trihydrate (liposomal irinotecan) to submit clinical and cost-effectiveness evidence for its use
Beale, S   +19 more
core   +2 more sources

A rapid and sensitive HPLC method for simultaneous determination of irinotecan hydrochloride and curcumin in co-delivered polymeric nanoparticles [PDF]

open access: yes, 2020
In recent years, a great deal of attention has been paid to the combined use of multiple antitumor drugs for better cancer treatment. The aims of the study are to construct a nanoparticle drug delivery system for the co-delivery of irinotecan ...
Sedlařík, Vladimír, Xiao, Haijun
core  

Circadian Rhythms in the CNS and Peripheral Clock Disorders: Chronopharmacological Findings on Antitumor Drugs

open access: yesJournal of Pharmacological Sciences, 2007
The effectiveness and toxicity of antitumor drugs vary depending on dosing time associated with the 24-h rhythms of biochemical, physiological, and behavioral processes under the control of the circadian clock.
Shigehiro Ohdo
doaj   +1 more source

Mesoporous Silica Nanoparticles With Customized Drug Ratio/Loading for Effective Treatment of Gemcitabine‐Resistant Pancreatic Tumors

open access: yesAdvanced NanoBiomed Research, EarlyView.
Redox responsive mesoporous silica nanoparticles (MSNs) were engineered to deliver gemcitabine (Gem) and cisplatin (cisPt) at defined ratios to overcome chemoresistance in pancreatic ductal adenocarcinoma (PDAC). Optimized Gem MSNs and Gem cisPt MSNs enhanced cytotoxicity in murine and human Gem resistant models, with select formulations inducing ...
Tamanna Binte Huq   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy